secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K/A
Filed at:   2025-08-28T23:59:59+00:00
Accession:  0001193125-25-191273
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst settles FIRDAPSE patent suit with Lupin; generic entry delayed to Feb 2035
--------------------------------------------------------------------------------

- Lupin receives license to market generic FIRDAPSE no earlier than February 25, 2035, if FDA-approved.
- All pending patent litigation between Catalyst/SERB and Lupin will be terminated.
- Previous settlements reached with Teva Pharmaceuticals and Inventia Healthcare Limited.
- Ongoing FIRDAPSE patent litigation against Hetero remains active.
- Confidential settlement agreement to be submitted to FTC and DOJ for review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525191273/0001193125-25-191273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525191273/d40349d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-191273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer